Saturday, January 24, 2015

President Obama Community College Concept Can Work By Offering A Genomics And Bioinformatic Technology Major

Barron’s Medical Journal And B. Bobby Graham ---Reporting From Washington, DC USA ---At The Phacilitate's Washington 11th Annual Cell & Gene Therapy Forum Stem Cells as Discovery and Research Tools Forum

President Obama Community College Concept Can Work By Offering A Genomics and Bioinformatic Technology Major:


Washington DC ( AP) ----- President Obama is on to something Congress Women Shelia Jackson Lee, Congressman Al Green, Texas Governor Gregg Abbott, Houston Mayor Annise Parker and Houston Community College System. If HCC located in Houston Texas will offered a Genomics and Bioinformatic technical major, this innovative idea will create several thousand jobs and the Free Community College program will pay for itself. President Obama Community College Free For Millions Of Students. On January 9, Obama announced a plan to make community college free for "all students if they attend classes at least half time and maintain a grade point average of 2.5 or better,"

Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism).

President Obama Community College Concept Can Work By Offering A Genomics and Bioinformatic Technical Major Bioinformatic is the science of computer information systems. As an academic field it involves the practice of information processing, and the engineering of information systems.

Laura Rathe Fine Art

Barron's Medical Journal Interview London England's Angel Biotechnology

The Genomics and Bioinformatic course should cover gene privacy administration; Gene data disseminate, management, and interpret of large, multi-scale cloud data.

Lets discuss the need for privacy, Female patients with breast cancer (n=100) completed a questionnaire assessing attitudes regarding concerns about privacy of genomic data.

Laboratory: Sunnyvale Center: Palo Alto Scientist Interview On Genomic & Infomatics

Results Most patients (83%) indicated that genomic data should be protected. However, only 13% had significant concerns regarding privacy of such data. Patients expressed more concern about insurance discrimination than employment discrimination (43% vs 28%, p<0.001). They expressed less concern about research institutions protecting the security of their molecular data than government agencies or drug companies (20% vs 38% vs 44%; p<0.001). Most did not express concern regarding the association of their genomic data with their name and personal identity (49% concerned), billing and insurance information (44% concerned), or clinical data (27% concerned). Significantly fewer patients were concerned about the association with clinical data than other data types (p<0.001). In the absence of direct benefit, patients were more willing to consent to sharing of deidentified than identified data with researchers not involved in their care (76% vs 60%; p<0.001). Most (85%) patients were willing to consent to DNA banking. Discussion While patients are opposed to indiscriminate release of genomic data, privacy does not appear to be their primary concern. Furthermore, we did not find any specific predictors of privacy concerns.

Conclusions Patients generally expressed low levels of concern regarding privacy of genomic data, and many expressed willingness to consent to sharing their genomic data with researchers.

Cancer therapy is increasingly personalized to the molecular characteristics of a particular patient and his/her tumor.1 The National Cancer Institute (NCI) defines personalized cancer therapy as the ‘application of genomic and molecular data to tailor medical care to individuals’.

2 Personalized cancer therapy has the potential to improve treatment response, reduce adverse effects, and reduce cost of care.3 In this paper, we refer to personalized, precision and genomically informed cancer therapy interchangeably. Similarly, although the terms ‘genetic’ and ‘genomic’ have distinct scientific meanings,3a we favored the more familiar ‘genetic’ in the questionnaire administered to patients and were not strict about the distinction.

Although patients and providers express an interest in genomically informed therapy,4 concerns regarding the privacy of genomic data have been raised, particularly in the context of research.5 6 Genomic data cannot be completely ‘deidenti- fied’, 7 8 thus these data pose a serious privacy risk. As a result, the storage and sharing of genomic data in the context of research is presently a topic of much debate.9

Data from a Gallup poll10 showed that medical privacy is important to people in the general population, and privacy concerns related to genetic testing and hereditary cancers have been raised.11 However, previous studies have asked general questions about medical privacy, such as ‘Who do you think should be allowed to see your medical records without your permission?’. 10 Such questions are not representative of current research being considered or conducted where identified data are collected for specific, explicitly defined purposes. Furthermore, many studies have focused almost exclusively on healthy participants, who did not have an established relationship with a research organization where they were receiving care. Thus, previous studies may not have considered the specific privacy concerns of patients with cancer, for whom molecular testing and genetic research may have direct and indirect benefits.

Finally, little is known about patients’ privacy concerns related to molecular testing in personalized cancer therapy, which mainly focuses on information related to somatic (as opposed to germline) mutations.12 In contrast with germline mutations, somatic mutations are not heritable. Thus, from a privacy perspective, they may be less concerning to patients.

Understanding patients’ privacy concerns regarding genomic data may help researchers and clinicians better address patient concerns, and may encourage participation in genomic studies.13 Further, patients rather than the general public are the most relevant population. Our results may also help to align the public policy debate with the concerns of patients, rather than the general public.

Cloud Data and The challenges posed by the need to disseminate, manage, and interpret large, multi-scale data pervade efforts to advance understanding of cancer biology and apply that knowledge in the clinic. For several years, the volume of data routinely generated by high-throughput research technologies has grown exponentially. The storage, transmission, and analysis of these data have become too costly for individual laboratories and most small to medium research organizations to support. For optimal progress to occur, access to large, valuable data collections and advanced computational capacity must be readily available to the widest possible audience.

“ On April 7, 2013, Dr. Harold Varmus and other members of the Institute's senior leadership issued a letter to NCI grantees seeking input on these and other computational challenges they encounter on an almost daily basis. Dr. Varmus stated that the NCI, as part of its ongoing investigations into next-generation computational capabilities to serve the research community, has begun exploring the possibility of creating one or more public "cancer knowledge clouds" in which data repositories would be co-located with advanced computing resources, thereby enabling researchers to bring their analytical tools and methods to the data. Reactions to this informal request for information were generally positive, with respondents focusing on six general themes: data access; computing capacity and infrastructure; data interoperability; training; usability; and governance.”

Based in part on this information, Dr. George Komatsoulis, then interim director of the Center for Biomedical Bioinformatic and Information Technology (CBIIT), which administers the National Cancer Informatics Program (NCIP), led the creation of a concept document describing a project to develop up to three cancer genomics cloud pilots for review by the cancer-research community. Dr. Komatsoulispresented the concept (time reference 05:58:00) at a joint meeting of the NCI Board of Scientific Advisors (BSA) and the National Cancer Advisory Board (NCAB) on June 24, 2013, where it received unanimous approval.

One great example of the type Bioinformatic technology is the Very Gene project. VeryGene is developed as a curated, web-accessible centralized database for the annotation of tissue-specific/enriched genes. It currently contains entries for 3960 human genes covering 128 normal tissue/cell types compiled from the expression profiling of two large microarray data sets [ref1, ref2]. It brings together much-needed information on preferred tissue/subcellular localization, functional annotation, pathway, mammalian phenotype, related diseases and targeting drug associated with any of these genes as a result of data integration from multiple sources. Information can be searched through gene, tissue and disease views and search result can be downloaded easily. We commit our best efforts to update and expand VeryGene as new and relevant information emerges

As an initiative toward systems biology, the VeryGene web server was developed to fill this gap. A significant effort has been made to integrate TSGs from two large-scale data analyses with respective information on subcellular localization, Gene Ontology, Reactome, KEGG pathway, Mouse Genome Informatics (MGI) Mammalian Phenotype, disease association, and targeting drugs. The current release carefully selected 3,960 annotated TSGs derived from 127 normal human tissues and cell types, including 5,672 gene-disease and 2,171 drug-target relationships. In addition to being a specialized source for TSGs, VeryGene can be used as a discovery tool by generating novel inferences. Some inherently useful but hidden relations among genes, diseases, drugs, and other important aspects can be inferred to form testable hypotheses.

Two interactive matrix views have been developed to provide users with intuitive, high-level summaries of expression data and from where they can easily move to levels of greater detail. The tissue-by-developmental stage matrix provides global overviews of the spatio-temporal expression patterns of genes. The tissue-by-gene matrix enables a comparison of expression patterns between genes. Both types of matrices can be expanded (and collapsed) along the tissue axis, based on the hierarchical organization of the anatomy. Rows and columns in the matrices can be selected to refine the data set. The matrices have been added as new tabs to the gene expression data summaries. These matrices can be accessed by searches using the Gene Expression Data Query and via links from the Mouse Developmental Anatomy Browser.

The Gene Expression Data Matrix is now accessible from the Access Data section of http://www.informatics.jax.org/expression.shtml It returns all of GXD's expression data in a tissue-by-developmental stage matrix. When using this matrix, users start with a high-level overview of GXD's data and then can interactively view and select expression data for the specific tissues and / or developmental stages of interest.

The standard Gene Expression Data Query now lets users define gene sets based on genomic location. One can, for example, search for disease candidate genes that have been mapped to a genomic region and are expressed in tissues affected by the disease.

Texas can be the leader Barron’s Medical Journal.

Saturday, January 10, 2015

State Of The Union For Breast Cancer

Barron’s Medial Journal and B.Bobby Graham reporting from Southern Methodist University (SMU) Southwestern's medical school in Dallas, Texas USA


State Of The Union For Breast Cancer:

Edited in Houston, Texas by Trenette Allen


Dallas ( AP ) ---- A women getting married in 2015 under the age of 40 has an 85% chance of surviving due to a breast cancer diagnosis. Genomics and Informatics is on the goal line. Barron’s Medical Journal says a cure may happen before the end of President Obama's second term.

Informatics is the science of information. As an academic field, it involves the practice of information processing, and the engineering of information systems. It studies the structure, algorithms, behavior, and interactions of natural and artificial systems which store, process, access, and communicate information.

We spoke with the Chief Information Officer of the informatics technology company Gen-Tek Inc. and what we found was a demand in the clinical trial setting and research center across the United States is at an all- time high. In fact, an Informatics engineer has a 97% chance of having a job offer before they graduate.

Breast cancer research two major developments: targeted treatments (small molecule inhibitors and monoclonal antibodies) and massive parallel sequencing of tumor genomes, also known as next-generation sequencing (NGS). By using these platforms, a great deal of information can be obtained in a very short time.

Cancer cells are dependent on oncogenic expression to maintain malignancy, and these can be used as predictive biomarkers. Examples include the following: oncogene addiction as in HER2 amplification in breast cancer, the KIT mutation in gastrointestinal stromal tumors, epidermal growth factor receptor mutations and/or amplification in nonsmall cell lung cancer, and the BRAF V600E mutation in melanoma. Data obtained from sequencing tumors from patients with breast cancer has revealed a high level of intertumor and intratumor heterogeneity, with very few highly recurrent mutations. It has also become apparent that not every tumor has an identifiable driver mutation, and not all drivers of metastatic disease or resistance have been identified. “It is only by harnessing the knowledge from intra- and intertumor heterogeneity that we will be able to realize the application of precision medicine.

The truth of the matter is, we treat cancer today, we guess. We take what we call the average results, put it in, and see if it works. If it doesn't work, oops, we'll try another drug. If it does work, we stop the drug. When you look back 10 years from now, it's almost barbaric.

Dr. Soon-Shiong 62-year-old native of South Africa can afford to be outspoken because of his immense wealth. He doesn't need to rely on the government or Big Pharma for funding. Soon-Shiong is certain that what he terms "the Dark Age of cancer treatment" is nearly over, and "the Enlightened Age" is about to begin.

The treatment doesn't need to be painful. Metastasis doesn't need to be a death sentence. Cancer could be a chronic disease...and treated towards the cure.

While the oncology world may cringe when he boasts, as he's prone to do, patients see him differently. He believes chemotherapy works best when administered in frequent, low doses and that in some cancers the traditional method of blasting a tumor with heavy doses of chemotherapy may actually be counterproductive - because it could induce cancer cells to escape the hostile environment, enter the bloodstream and find a new home. Soon-Shiong has teamed with Blackberry to produce a device that will identify for patients and doctors what they need to make more informed decisions.

Genomics is a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). We then ask Rose is her company doing any work with Genomics for breast cancer and if so explain the process. Genomics is the Gaussian processes in action, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Sam Houston to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Sam Houston has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Sam Houston for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. Breast cancer researchers and scientists are ahead of the curve with several new technologies based on nanoparticles and semi conductors namely genomics and treatments. The field of genomics is caught in a data deluge. Targeted breast cancer DNA sequencing is becoming faster and cheaper at a pace far outstripping Moore’s law, which describes the rate at which computing gets faster and cheaper.

The result is that the ability to determine targeted breast cancer DNA sequences is starting to outrun the ability of researchers to store, transmit and especially to analyze the data. The cost of sequencing a human genome — all three billion bases of DNA in a set of human chromosomes — plunged to $10,000.00 which means genomics breast cancer DNA sequencing is around $3,000.00. The lower cost, along with increasing speed, has led to a huge increase in how much breast cancer sequencing data is being produced.

Numerous investigations have shown that both tissue and cell distribution profiles of anti-cancer drugs can be controlled by their entrapment in submicronic colloidal systems (nanoparticles). The rationale behind this approach is to increase antitumor efficacy, while reducing systemic side-effects. This review provides an update of tumor targeting with conventional or long-circulating nanoparticles. The invivo fate of these systems, after intravascular or tumoral administration, is discussed, as well as the mechanism involved in tumor regression. Nanoparticles are also a benefit for the selective delivery of oligonucleotides to tumor cells. Moreover, certain types of nanoparticles showed some interesting capacity to reverse MDR resistance, which is a major problem in chemotherapy. The first experiments, aiming to decorate nanoparticles with molecular ligand for active targeting of cancerous cells.

Miniaturization will allow the tools for many different tests to be situated together on the same small device. Hybrid Sam Houston researchers say that nanotechnology will allow them to run many diagnostic tests simultaneously. Nanoparticles nanoshells is use to antibodies that recognize cancer cells. Sam Houston scientists envision letting these nanoshells seek out their cancerous targets, then apply near-infrared light. The heat generated by the light-absorbing nanoshells can successfully kill breast cancer tumor cells while leaving neighboring cells intact.